日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer

VIKTORIA-1试验:Gedatolisib联合Fulvestrant,加或不加Palbociclib治疗激素受体阳性/HER2-/PIK3CA野生型晚期乳腺癌

Hurvitz, Sara A; Layman, Rachel M; Curigliano, Giuseppe; André, Fabrice; Cristofanilli, Massimo; Kim, Sung-Bae; Martínez Rodríguez, Jorge Luis; Nadal, Jorge C; Kim, Gun Min; Lo, Louisa; Remolina-Bonilla, Yuly A; Rosselli, Geronimo; Emile, George; Korbenfeld, Ernesto; Puig, Juan Manuel; Wesolowski, Robert; Martin, Miguel; Ring, Alistair; Han, Hyo S; Giordano, Antonio; Mutka, Sarah C; Moss, Keren; Suzuki, Sam; Sullivan, Brian; Gorbatchevsky, Igor; Pistilli, Barbara

Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial

阿贝西利联合氟维司群治疗CDK4/6抑制剂治疗进展后的晚期乳腺癌:MONARCH III期临床试验结果

Kalinsky, Kevin; Bianchini, Giampaolo; Hamilton, Erika; Graff, Stephanie L; Park, Kyong Hwa; Jeselsohn, Rinath; Demirci, Umut; Martin, Miguel; Layman, Rachel M; Hurvitz, Sara A; Sammons, Sarah; Kaufman, Peter A; Muñoz, Montserrat; Lai, Jiun-I; Knoderer, Holly; Sandoval, Cynthia; Chawla, Aarti R; Nguyen, Bastien; Zhou, Yanhong; Ravenberg, Elizabeth; Litchfield, Lacey M; Smyth, Lillian; Wander, Seth A

Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical Trial

瑞博西尼联合内分泌治疗激素受体阳性/ERBB2阴性早期乳腺癌:NATALEE随机临床试验的4年结果

Fasching, Peter A; Stroyakovskiy, Daniil; Yardley, Denise A; Huang, Chiun-Sheng; Crown, John; Bardia, Aditya; Chia, Stephen; Im, Seock-Ah; Martin, Miguel; Xu, Binghe; Loi, Sherene; Barrios, Carlos; Untch, Michael; Moroose, Rebecca; Visco, Frances; Hortobagyi, Gabriel N; Slamon, Dennis J; Fresco, Rodrigo; Zarate, Juan Pablo; Li, Zheng; Waters, Sorcha; Hurvitz, Sara A

Cardiotoxic Effects of Antibody Drug Conjugates vs Standard Chemotherapy in ERBB2-Positive Advanced Breast Cancer: A Systematic Review and Meta-Analysis

抗体药物偶联物与标准化疗在ERBB2阳性晚期乳腺癌中的心脏毒性作用:系统评价和荟萃分析

Seth, Lakshya; Bhave, Aditya; Kollapaneni, Sai; Shah, Viraj; Nahle, Tarek; Blaes, Anne; Dent, Susan; Hurvitz, Sara A; Guha, Avirup

Expert consensus on treating HR+/HER2- metastatic breast cancer based on real-world practice patterns observed in the RETRACT survey of US oncologists

基于RETRACT调查中观察到的美国肿瘤学家真实世界实践模式,专家就HR+/HER2-转移性乳腺癌的治疗达成共识

Rugo, Hope S; Bardia, Aditya; Gradishar, William J; Hamilton, Erika P; Hurvitz, Sara A; Jhaveri, Komal; Mahtani, Reshma; Tolaney, Sara M

Inflammation and dimensions of fatigue in women with early stage breast cancer: A longitudinal examination

早期乳腺癌女性的炎症和疲劳程度:一项纵向研究

Bower, Julienne E; Radin, Arielle; Ganz, Patricia A; Irwin, Michael R; Cole, Steve W; Petersen, Laura; Asher, Arash; Hurvitz, Sara A; Crespi, Catherine M

Characterization of the safety profile of trastuzumab deruxtecan by dose: a pooled analysis across DESTINY studies

按剂量划分的曲妥珠单抗德鲁西替康安全性特征:DESTINY 研究的汇总分析

Park, Yeon Hee; Cortes, Javier; Modi, Shanu; Hurvitz, Sara A; Bianchini, Giampaolo; Iwata, Hiroji; Shitara, Kohei; Siena, Salvatore; Goto, Yasushi; Ku, Geoffrey Y; Powell, Charles A; Swain, Sandra M; Arunachalam, Meena; Janek, Martin; Cheng, Yingkai; Chu, Changan; Verma, Purnima; Kuptsova-Clarkson, Nataliya; Mathias, Elton; Goodman, Erin; Rugo, Hope S

PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degraders for Treatment of Estrogen Receptor-Positive Advanced Breast Cancer

用于治疗雌激素受体阳性晚期乳腺癌的蛋白水解靶向嵌合体(PROTAC)雌激素受体降解剂

Hamilton, Erika P; Jeselsohn, Rinath M; Vahdat, Linda T; Hurvitz, Sara A

Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial

曲妥珠单抗德鲁替康与曲妥珠单抗恩坦辛治疗HER2阳性转移性乳腺癌:DESTINY-Breast03试验的长期生存分析

Cortés, Javier; Hurvitz, Sara A; Im, Seock-Ah; Iwata, Hiroji; Curigliano, Giuseppe; Kim, Sung-Bae; Chiu, Joanne W Y; Pedrini, Jose L; Li, Wei; Yonemori, Kan; Bianchini, Giampaolo; Loi, Sherene; Borges, Giuliano S; Wang, Xian; Bachelot, Thomas; Nakatani, Shunsuke; Ashfaque, Shahid; Liang, Zhengkang; Egorov, Anton; Hamilton, Erika

Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression

随机III期ASCENT临床试验在转移性三阴性乳腺癌中的最终结果以及人表皮生长因子受体2和滋养层细胞表面抗原2表达与预后之间的关联

Bardia, Aditya; Rugo, Hope S; Tolaney, Sara M; Loirat, Delphine; Punie, Kevin; Oliveira, Mafalda; Brufsky, Adam; Kalinsky, Kevin; Cortés, Javier; Shaughnessy, Joyce O'; Diéras, Véronique; Carey, Lisa A; Gianni, Luca; Piccart-Gebhart, Martine; Loibl, Sibylle; Yoon, Oh Kyu; Pan, Yang; Hofsess, Scott; Phan, See-Chun; Hurvitz, Sara A